Bluejay Diagnostics (BJDX) Gains from Investment Securities (2020 - 2026)
Bluejay Diagnostics recorded quarterly Gains from Investment Securities of $2927.0 in Q1 2026, up 456.08% quarter-over-quarter from -$822.0 in Q4 2025, and up 3965.28% year-over-year from $72.0 in Q1 2025.
Bluejay Diagnostics' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $2927.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 3965.28% year-over-year to $2927.0; the TTM figure through Mar 2026 stood at $17281.0 (up 23901.39% YoY), while the FY2025 annual figure was $5.0, down 72.22% from the prior year.
- Gains from Investment Securities came in at $2927.0 for Q1 2026 at Bluejay Diagnostics, up from -$822.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $35858.0 in Q2 2023 to a low of -$12597.0 in Q4 2022.
- A 5-year average of $6628.6 and a median of $2927.0 in 2026 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities plunged 193.15% in 2022 and jumped 3965.28% in 2026, its largest moves.
- Bluejay Diagnostics' Gains from Investment Securities stood at -$12597.0 in 2022, then soared by 127.92% to $3517.0 in 2023, then soared by 231.5% to $11659.0 in 2024, then slumped by 107.05% to -$822.0 in 2025, then jumped by 456.08% to $2927.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $2927.0, -$822.0, and $32.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,927.00 |
| Mar 31, 2026 | 2,927.00 |
| Dec 31, 2025 | -822.00 |
| Dec 31, 2025 | -822.00 |
| Sep 30, 2025 | 32.00 |
| Sep 30, 2025 | 32.00 |
| Jun 30, 2025 | 43.00 |
| Jun 30, 2025 | 43.00 |
| Mar 31, 2025 | 72.00 |
| Mar 31, 2025 | 72.00 |
| Dec 31, 2024 | 11,659.00 |
| Dec 31, 2024 | 11,659.00 |
| Sep 30, 2024 | 5,047.00 |
| Sep 30, 2024 | 5,047.00 |
| Jun 30, 2024 | 3,721.00 |
| Jun 30, 2024 | 3,721.00 |
| Mar 31, 2024 | 29,770.00 |
| Mar 31, 2024 | 29,770.00 |
| Dec 31, 2023 | 3,517.00 |
| Dec 31, 2023 | 3,517.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 35,858.00 |
| Jun 30, 2023 | 35,858.00 |
| Mar 31, 2023 | 20,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | -12,597.00 |
| Dec 31, 2022 | -12,597.00 |
| Sep 30, 2022 | -1,596.00 |
| Sep 30, 2022 | -1,596.00 |
| Jun 30, 2022 | 14,844.00 |
| Jun 30, 2022 | 14,844.00 |
| Mar 31, 2022 | -788.00 |
| Mar 31, 2022 | -788.00 |
| Dec 31, 2021 | 13,523.00 |
| Dec 31, 2021 | 13,523.00 |
| Sep 30, 2021 | 190,000.00 |
| Sep 30, 2021 | 190,000.00 |
| Dec 31, 2020 | 375,826.00 |
| Dec 31, 2020 | 375,826.00 |